Stockreport

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications [Yahoo! Finance]

Nkarta, Inc.  (NKTX) 
PDF IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data from Ntrust-1 and Ntrust-2 planne [Read more]